| General Information | |
|---|---|
| ZINC ID | ZINC000169329794 |
| Molecular Weight (Da) | 385 |
| SMILES | O=C1/C(=C/c2cccc(OCc3ccc(Cl)cc3)c2)N=C2SCCCN12 |
| Molecular Formula | C20Cl1N2O2S1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 106.849 |
| HBA | 4 |
| HBD | 0 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 26 |
| LogP | 4.521 |
| Activity (Ki) in nM | 4073.803 |
| Polar Surface Area (PSA) | 67.2 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | 0 |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.02330136 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 12 |
| Fraction csp3 | 0.2 |
| Ilogp | 3.66 |
| Xlogp3 | 4.68 |
| Wlogp | 3.57 |
| Mlogp | 3.48 |
| Silicos-it log p | 5.1 |
| Consensus log p | 4.1 |
| Esol log s | -5.25 |
| Esol solubility (mg/ml) | 0.00215 |
| Esol solubility (mol/l) | 0.0000056 |
| Esol class | Moderately |
| Ali log s | -5.82 |
| Ali solubility (mg/ml) | 0.000584 |
| Ali solubility (mol/l) | 0.00000152 |
| Ali class | Moderately |
| Silicos-it logsw | -6.67 |
| Silicos-it solubility (mg/ml) | 0.0000825 |
| Silicos-it solubility (mol/l) | 0.00000021 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.32 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 1 |
| Brenk number of alerts | 1 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.64 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.124 |
| Logd | 4.109 |
| Logp | 4.211 |
| F (20%) | 0.001 |
| F (30%) | 0.003 |
| Mdck | 1.45E-05 |
| Ppb | 1.0016 |
| Vdss | 0.768 |
| Fu | 0.0106 |
| Cyp1a2-inh | 0.954 |
| Cyp1a2-sub | 0.32 |
| Cyp2c19-inh | 0.897 |
| Cyp2c19-sub | 0.08 |
| Cl | 4.913 |
| T12 | 0.072 |
| H-ht | 0.784 |
| Dili | 0.958 |
| Roa | 0.107 |
| Fdamdd | 0.87 |
| Skinsen | 0.212 |
| Ec | 0.003 |
| Ei | 0.012 |
| Respiratory | 0.048 |
| Bcf | 2.723 |
| Igc50 | 4.446 |
| Lc50 | 5.862 |
| Lc50dm | 6.107 |
| Nr-ar | 0.009 |
| Nr-ar-lbd | 0.014 |
| Nr-ahr | 0.936 |
| Nr-aromatase | 0.978 |
| Nr-er | 0.968 |
| Nr-er-lbd | 0.08 |
| Nr-ppar-gamma | 0.122 |
| Sr-are | 0.918 |
| Sr-atad5 | 0.591 |
| Sr-hse | 0.351 |
| Sr-mmp | 0.936 |
| Sr-p53 | 0.922 |
| Vol | 369.816 |
| Dense | 1.039 |
| Flex | 0.167 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 1 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 4 |
| Acute aquatic toxicity | 4 |
| Toxicophores | 1 |
| Qed | 0.724 |
| Synth | 2.493 |
| Fsp3 | 0.2 |
| Mce-18 | 45 |
| Natural product-likeness | -1.389 |
| Alarm nmr | 4 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 4 |
| Gsk | Rejected |
| Goldentriangle | Accepted |